Elanco Animal Health Incorporated
ELAN
Clasificación en acciones
#1886
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Precio por acción
$22.45
Capitalización bursátil
$11.21B
Cambio (1 día)
-1.08%
Cambio (1 año)
3.84%
País
US
Comercio Elanco Animal Health Incorporated (ELAN)
Categoría
Healthcare
Ingresos de Elanco Animal Health Incorporated (ELAN)
Ingresos en Jun 2026 TTM: $5.02B
Según los últimos informes financieros de Elanco Animal Health Incorporated, los ingresos actuales de la empresa (TTM) son $5.02B. En 2023, la empresa obtuvo unos ingresos de $4.42B un aumento con respecto a los ingresos del año 2022, que fueron de $4.41B. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Elanco Animal Health Incorporated desde 2015 hasta 2026
Ingresos al final de cada año
| Año | Ingresos | Cambiar |
|---|---|---|
| 2026 (TTM) | $5.02B | 13.09% |
| 2024 | $4.44B | 0.50% |
| 2023 | $4.42B | 0.14% |
| 2022 | $4.41B | -7.41% |
| 2021 | $4.76B | 45.54% |
| 2020 | $3.27B | 6.59% |
| 2019 | $3.07B | 0.14% |
| 2018 | $3.07B | 6.15% |
| 2017 | $2.89B | -0.84% |
| 2016 | $2.91B | 0.15% |
| 2015 | $2.91B | 0.00% |
Ingresos de empresas similares o competidoras
| Empresa | Ingresos | Diferencia de ingresos | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 31.71% |
IN
|
